|
1
|
Wang X, Chen CW and Armstrong SA: The role
of DOT1L in the maintenance of leukemia gene expression. Curr Opin
Genet Dev. 36:68–72. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lacoste N, Utley RT, Hunter JM, Poirier GG
and Côte J: Disruptor of telomeric silencing-1 is a
chromatin-specific histone H3 methyltransferase. J Biol Chem.
277:30421–30424. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Farooq Z, Banday S, Pandita TK and Altaf
M: The many faces of histone H3K79 methylation. Mutat Res Rev Mutat
Res. 768:46–52. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee JY and Kong G: DOT1L: A new
therapeutic target for aggressive breast cancer. Oncotarget.
6:30451–30452. 2015.PubMed/NCBI
|
|
5
|
Kryczek I, Lin Y, Nagarsheth N, Peng D,
Zhao L, Zhao E, Vatan L, Szeliga W, Dou Y, Owens S, et al:
IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3
transcription factor activation and induction of the
methyltransferase DOT1L. Immunity. 40:772–784. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nguyen AT, Taranova O, He J and Zhang Y:
DOT1L, the H3K79 methyltransferase, is required for
MLL-AF9-mediated leukemogenesis. Blood. 117:6912–6922. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oktyabri D, Ishimura A, Tange S, Terashima
M and Suzuki T: DOT1L histone methyltransferase regulates the
expression of BCAT1 and is involved in sphere formation and cell
migration of breast cancer cell lines. Biochimie. 123:20–31. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Caparello C, Meijer LL, Garajova I,
Falcone A, Le Large TY, Funel N, Kazemier G, Peters GJ, Vasile E
and Giovannetti E: FOLFIRINOX and translational studies: Towards
personalized therapy in pancreatic cancer. World J Gastroenterol.
22:6987–7005. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takaori K, Bassi C, Biankin A, Brunner TB,
Cataldo I, Campbell F, Cunningham D, Falconi M, Frampton AE, Furuse
J, et al: IAP/EPC study group on the clinical managements of
pancreatic cancer: International Association of Pancreatology
(IAP)/European Pancreatic Club (EPC) consensus review of guidelines
for the treatment of pancreatic cancer. Pancreatology. 16:14–27.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gall TM, Tsakok M, Wasan H and Jiao LR:
Pancreatic cancer: Current management and treatment strategies.
Postgrad Med J. 91:601–607. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wagner M, Redaelli C, Lietz M, Seiler CA,
Friess H and Büchler MW: Curative resection is the single most
important factor determining outcome in patients with pancreatic
adenocarcinoma. Br J Surg. 91:586–594. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Badger SA, Brant JL, Jones C, McClements
J, Loughrey MB, Taylor MA, Diamond T and McKie LD: The role of
surgery for pancreatic cancer: A 12-year review of patient outcome.
Ulster Med J. 79:70–75. 2010.PubMed/NCBI
|
|
13
|
Simon R, Mirlacher M and Sauter G: Tissue
microarrays. Methods Mol Med. 114:257–268. 2005.PubMed/NCBI
|
|
14
|
Helbig D, Ihle MA, Pütz K, Tantcheva-Poor
I, Mauch C, Büttner R and Quaas A: Oncogene and therapeutic target
analyses in atypical fibroxanthomas and pleomorphic dermal
sarcomas. Oncotarget. 7:21763–21774. 2016.PubMed/NCBI
|
|
15
|
Liu W, Deng L, Song Y and Redell M: DOT1L
inhibition sensitizes MLL-rearranged AML to chemotherapy. PLoS One.
9:e982702014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stein EM and Tallman MS: Mixed lineage
rearranged leukaemia: Pathogenesis and targeting DOT1L. Curr Opin
Hematol. 22:92–96. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deshpande AJ, Chen L, Fazio M, Sinha AU,
Bernt KM, Banka D, Dias S, Chang J, Olhava EJ, Daigle SR, et al:
Leukemic transformation by the MLL-AF6 fusion oncogene requires the
H3K79 methyltransferase Dot1l. Blood. 121:2533–2541. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Okada Y, Feng Q, Lin Y, Jiang Q, Li Y,
Coffield VM, Su L, Xu G and Zhang Y: hDOT1L links histone
methylation to leukemogenesis. Cell. 121:167–178. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wong M, Polly P and Liu T: The histone
methyltransferase DOT1L: Regulatory functions and a cancer therapy
target. Am J Cancer Res. 5:2823–2837. 2015.PubMed/NCBI
|
|
20
|
Zhang L, Deng L, Chen F, Yao Y, Wu B, Wei
L, Mo Q and Song Y: Inhibition of histone H3K79 methylation
selectively inhibits proliferation, self-renewal and metastatic
potential of breast cancer. Oncotarget. 5:10665–10677. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cho MH, Park JH, Choi HJ, Park MK, Won HY,
Park YJ, Lee CH, Oh SH, Song YS, Kim HS, et al: DOT1L cooperates
with the c-Myc-p300 complex to epigenetically derepress CDH1
transcription factors in breast cancer progression. Nat Commun.
6:78212015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim W, Choi M and Kim JE: The histone
methyltransferase Dot1/DOT1L as a critical regulator of the cell
cycle. Cell Cycle. 13:726–738. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Daigle SR, Olhava EJ, Therkelsen CA,
Basavapathruni A, Jin L, Boriack-Sjodin PA, Allain CJ, Klaus CR,
Raimondi A, Scott MP, et al: Potent inhibition of DOT1L as
treatment of MLL-fusion leukemia. Blood. 122:1017–1025. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Klaus CR, Iwanowicz D, Johnston D,
Campbell CA, Smith JJ, Moyer MP, Copeland RA, Olhava EJ, Scott MP,
Pollock RM, et al: DOT1L inhibitor EPZ-5676 displays synergistic
antiproliferative activity in combination with standard of care
drugs and hypomethylating agents in MLL-rearranged leukemia cells.
J Pharmacol Exp Ther. 350:646–656. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Morris JP IV, Wang SC and Hebrok M: KRAS,
Hedgehog, Wnt and the twisted developmental biology of pancreatic
ductal adenocarcinoma. Nat Rev Cancer. 10:683–695. 2010. View Article : Google Scholar : PubMed/NCBI
|
